AnaptysBio is a clinical stage biotechnology company developing immunology therapeutic product candidates focused on immune control mechanisms applicable to inflammation and immuno-oncology indications. Co.'s wholly-owned antibody programs include: imsidolimab, which inhibits the interleukin-36 receptor and is being developed for the treatment of multiple dermatological inflammatory diseases; ANB030, which is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, which is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The ANAB stock yearly return is shown above.
The yearly return on the ANAB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANAB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|